Market Underperform / Speculative Risk; Target Price $22 "Why does AMLN Takeover Chatter Always Come Before Slow Bydureon Rx Figures?"

1. Amylin Pharmaceuticals Inc. (AMLN)
®
COMPANY UPDATE Michael G. King, Jr.
212-430-1794
mking@rodm.com
LIFE SCIENCES
May 21, 2012 Market Underperform / Speculative
Risk
Why does AMLN Takeover Chatter Always Come Before Slow Bydureon Rx Figures?
Updated GLP-1 Rx data for the week ending May 11th.
MARKET DATA 5/18/2012
Wolters-Kluwer reported that there were 3,161 new starts (NRx) on
Price $26.80 Bydureon for the week of May 5 th to May 11th (week 13 of the launch).
Exchange NASDAQ On an absolute basis, new starts were down more than 5% from the
Target Price $22.00 previous week’s total of 3,332, interrupting the four week streak of gains.
52 Wk Hi - Low $28.02 - $8.03
NRx for the entire GLP-1 class was down slightly more than 4% (29,169
Market Cap(MM) $4,364.4
EV(MM) $5,734.1
vs. 30,388), giving back most of the gains seen in the previous week’s
Shares Out (MM) 162.9 4% sequential rise.
Public Mkt Float (MM) 1,617.8 NRx for the overall exenatide franchise fell faster than the overall
Avg. Daily Vol 4,153,756 GLP-1 class. Exenatide NRx dipped more than 6% sequentially driven
Short Interest 10,496,372 by significant decreases in Bydureon (discussed above) and Byetta (NRx
BALANCE SHEET METRICS was 9,783), As a result, Exenatide NRx market share dipped to 44.4%,
down from last week’s total of 45.2%. Bydureon’s NRx market share was
Cash (MM) $204.1
10.8% (down from last week’s total of 11.0%) and Byetta’s share total
LTD (MM) $714.8
Total Debt/Capital NA
was 33.5%, down from 34.3%. Table 1 details the comparison of NRx
Cash/Share $1.39 results for the week compared to the 4-week moving averages prior to
Book Value(MM) NA the launch. Figures 1 and 2 detail the NRx figures and market share.
Book Value/Share $0.05 The entire GLP-1 class gave back most of last week’s TRx gains,
EARNINGS DATA ($) however, the dip in Bydureon TRx is potentially worrisome. We
recommend investors focus on total Rx (TRx) as the key metric, as it
FY - Dec 2010A 2011A 2012E
relates directly to revenues, to judge the exenatide franchise. Bydureon
Q1 (Mar) (0.27) (0.26) (0.66)A
Q2 (Jun) (0.31) (0.22) (0.51)
posted TRx of 5,043, down 2.1% from last week’s total of 5,155. This is
Q3 (Sep) (0.35) (0.09) (0.44) the first sequentially down week in TRx we have seen for Bydureon.
Q4 (Dec) (0.13) (3.16) (0.40) Given that the product only launched 13 weeks ago, we are surprised to
Full Year EPS (1.06) (3.73) (2.03) see growth levelling off as quickly as this week's figures appear to
Revenue (MM) 669.0 650.7 624.9 indicate. Bydureon TRx market share rose modestly to 7.1% from 6.9%.
Byetta TRx figures were hit even harder, failing 8.5% from 28,314 to
25,890 for the week. These figures translate to a fall in market share for
VALUATION METRICS
Byetta from 38.0% to 36.6%. TRx was the entire class fell almost 5% to
Price/Earnings NM NM NM 70,810. Table 2 details the comparison of TRx results for the week
EV/Revenue 8.6x 8.8x 9.2x
compared to the 4-week moving averages prior to the launch.
Y/Y EPS Growth 251.9% NM
EV/Sales Overall, this week’s report appears to be as disappointing as last
week’s was encouraging. Last week’s report showed gains across the
INDICES board for AMLN and the GLP-1 class. This week those gains were given
DJIA 12,369.4 back, and AMLN products were hit harder than Victoza. Additionally, we
SP-500 1,295.2 pulled the weekly Rx statistics from Victoza two years ago (Figure 3 and
NASDAQ 2,478.5 Table 5). Despite the GLP-1 market growing some 20% in the two years
NBI 1,251.0 since the launch of Victoza, the absolute NRx generated by Bydureon is
1 Year Price History
almost half that achieved by Victoza at the same point in the respective
launches.
30
25
20
We maintain our Market Underperform rating and a $22 target. We
15 continue to believe our skepticism is justified given the company’s history
10
5
of poor execution and the most recent quarter’s fair-to-middling (in our
Q1 Q2 Q3 Q1 Q2
2012
50
opinion) results. We continue to believe the exenatide franchise is
40
30
unwanted by those who already have a presence in the diabetes space
20
10 and a sub-optimal set of assets for those companies to gain a presence
0
Created by BlueMatrix in the diabetes/metabolic disease space. In our opinion, AMLN
management would have done well to accept the BMY offer of $22 per
share; justifying our price target on the shares.
For definitions and the distribution of analyst ratings, and other disclosures, please refer to pages 8 - 9 of this report.

2. Amylin Pharmaceuticals Inc. May 21, 2012
Figure 1. NRx Absolute Figures by Week
Figure 2. NRx Market Share by Week
RODMAN & RENSHAW EQUITY RESEARCH 2

3. Amylin Pharmaceuticals Inc. May 21, 2012
Figure 3. Comparison of Victoza and Bydureon Launches (Absolute NRx)
Figure 4. Absolute TRx by Week
RODMAN & RENSHAW EQUITY RESEARCH 3

4. Amylin Pharmaceuticals Inc. May 21, 2012
Table 1. Changes in NRx from Week Ending 5/11 Vs. Moving Averages Prior to Bydureon Approval
4-week
Moving
Changes in NRx 5/11/2012 Variance
Averages
1/27/2012
BYDUREON 3,161 3,161
BYETTA 11,412 9,783 (1,629)
Total Exenetide Franchise 11,412 12,944 1,532
VICTOZA 15,063 16,225 1,162
TOTAL GLP-1 New Rx 26,475 29,169 2,694
Market Share % of NRx
BYDUREON 10.8% 10.8%
BYETTA 43.1% 33.5% -9.6%
Total Exenetide % 43.1% 44.4% 1.3%
VICTOZA 56.9% 55.6% -1.3%
Table 2. Changes in TRx from Week Ending 5/11 Vs. Moving Averages Prior to Bydureon Approval
4-week
Moving
Changes in TRx 5/11/2012 Variance
Averages
1/27/2012
BYDUREON 5,043 5,043
BYETTA 28,429 25,890 (2,539)
Total Exenetide Franchise 28,429 30,933 2,505
VICTOZA 36,009 39,877 3,869
TOTAL GLP-1 Rx 64,437 70,810 6,373
Market Share % of TRx
BYDUREON 7.1% 7.1%
BYETTA 43.8% 36.6% -7.2%
Total Exenetide % 43.8% 43.7% -0.1%
VICTOZA 56.2% 56.3% 0.1%
Upcoming Milestones
Product Event Timing
Corporate Annual meeting and proxy fight May 24, 2012
Bydureon Secure EU partner 2012
Metreleptin Potential EU orphan designation 1H12
Exenatide suspension Once-weekly Phase III initiation 2Q12/3Q12
Bydureon Launch pen/device 4Q12/1Q13
Exenatide suspension Once-monthly Phase III initiation 2013
RODMAN & RENSHAW EQUITY RESEARCH 4

5. Amylin Pharmaceuticals Inc. May 21, 2012
Table 3. New Prescription Starts (NRx) for the GLP-1 Market by Week
Total New Rx (NRx)
Product 1/6/2012 1/13/2012 1/20/2012 1/27/2012 2/3/2012 2/10/2012 2/17/2012 2/24/2012 3/2/2012 3/9/2012 3/16/2012 3/23/2012 3/30/2012 4/6/2012 4/13/2012 4/20/2012 4/27/2012 5/4/2012 5/11/2012
Week 1 2 3 4 5 6 7 8 9 10 11 12 13
BYDUREON
TOTAL BYDUREON Rx 1 15 386 894 1,275 1,845 2,073 2,467 2,719 2,940 2,801 2,963 3,224 3,332 3,161
Sequential Growth 2473.33% 131.61% 42.62% 44.71% 12.36% 19.01% 10.21% 8.13% -4.73% 5.78% 8.81% 3.35% -5.13%
4-wk Moving Avg. 134 324 643 1,100 1,522 1,915 2,276 2,550 2,732 2,856 2,982 3,080 3,170
BYETTA
10MCG/0.04 7,866 8,353 7,915 8,106 8,854 8,047 7,485 7,556 7,517 7,911 7,336 7,148 7,433 7,255 6,762 6,841 7,055 7,259 6,753
5MCG/0.02 3,198 3,403 3,394 3,413 3,569 3,465 3,199 3,158 3,274 3,486 3,189 3,173 3,141 3,089 2,872 2,974 2,987 3,155 3,030
TOTAL BYETTA Rx 11,064 11,756 11,309 11,519 12,423 11,512 10,684 10,714 10,791 11,397 10,525 10,321 10,574 10,344 9,634 9,815 10,042 10,414 9,783
Sequential Growth 18.78% 6.25% -3.80% 1.86% 7.85% -7.33% -7.19% 0.28% 0.72% 5.62% -7.65% -1.94% 2.45% -2.18% -6.86% 1.88% 2.31% 3.70% -6.06%
4-wk Moving Avg. 10,550 10,745 10,861 11,412 11,752 11,691 11,535 11,333 10,925 10,897 10,857 10,759 10,704 10,441 10,218 10,092 9,959 9,976 10,014
TOTAL EXENETIDE FRANCHISE 11,064 11,756 11,309 11,519 12,424 11,527 11,070 11,608 12,066 13,242 12,598 12,788 13,293 13,284 12,435 12,778 13,266 13,746 12,944
Sequential Growth 18.78% 6.25% -3.80% 1.86% 7.86% -7.22% -3.96% 4.86% 3.95% 9.75% -4.86% 1.51% 3.95% -0.07% -6.39% 2.76% 3.82% 3.62% -5.83%
4-wk Moving Avg. 10,550 10,745 10,861 11,412 11,752 11,695 11,635 11,657 11,568 11,997 12,379 12,674 12,980 12,991 12,950 12,948 12,941 13,056 13,184
~
VICTOZA
2-PACK 5,010 5,301 5,214 5,162 5,615 5,389 5,303 5,334 5,431 5,711 5,381 5,467 5,356 5,306 5,527 5,719 5,539 5,654 5,680
3-PACK 9,626 9,944 9,927 10,067 10,472 10,439 10,382 9,958 10,330 11,012 10,101 10,417 10,422 10,247 9,944 10,484 10,415 10,988 10,545
TOTAL VICTOZA Rx 14,636 15,245 15,141 15,229 16,087 15,828 15,685 15,292 15,761 16,723 15,482 15,884 15,778 15,553 15,471 16,203 15,954 16,642 16,225
Sequential Growth 19.12% 4.16% -0.68% 0.58% 5.63% -1.61% -0.90% -2.51% 3.07% 6.10% -7.42% 2.60% -0.67% -1.43% -0.53% 4.73% -1.54% 4.31% -2.51%
4-wk Moving Avg. 13,899 14,148 14,327 15,063 15,426 15,571 15,707 15,723 15,642 15,865 15,815 15,963 15,967 15,674 15,672 15,751 15,795 16,068 16,256
TOTAL GLP-1 NRx 25,700 27,001 26,450 26,748 28,511 27,355 26,755 26,900 27,827 29,965 28,080 28,672 29,071 28,837 27,906 28,981 29,220 30,388 29,169
Sequential Growth 18.97% 5.06% -2.04% 1.13% 6.59% -4.05% -2.19% 0.54% 3.45% 7.68% -6.29% 2.11% 1.39% -0.80% -3.23% 3.85% 0.82% 4.00% -4.01%
4-wk Moving Avg. 24,448 24,893 25,188 26,475 27,178 27,266 27,342 27,380 27,209 27,862 28,193 28,636 28,947 28,665 28,622 28,699 28,736 29,124 29,440
% of NRx by Product
Product 1/6/2012 1/13/2012 1/20/2012 1/27/2012 2/3/2012 2/10/2012 2/17/2012 2/24/2012 3/2/2012 3/9/2012 3/16/2012 3/23/2012 3/30/2012 4/6/2012 4/13/2012 4/20/2012 4/27/2012 5/4/2012 5/11/2012
Week 1 2 3 4 5 6 7 8 9 10 11 12 13
BYDUREON 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 1.4% 3.3% 4.6% 6.2% 7.4% 8.6% 9.4% 10.2% 10.0% 10.2% 11.0% 11.0% 10.8%
BYETTA 43.1% 43.5% 42.8% 43.1% 43.6% 42.1% 39.9% 39.8% 38.8% 38.0% 37.5% 36.0% 36.4% 35.9% 34.5% 33.9% 34.4% 34.3% 33.5%
Total Exenetide % 43.1% 43.5% 42.8% 43.1% 43.6% 42.1% 41.4% 43.2% 43.4% 44.2% 44.9% 44.6% 45.7% 46.1% 44.6% 44.1% 45.4% 45.2% 44.4%
VICTOZA 56.9% 56.5% 57.2% 56.9% 56.4% 57.9% 58.6% 56.8% 56.6% 55.8% 55.1% 55.4% 54.3% 53.9% 55.4% 55.9% 54.6% 54.8% 55.6%
RODMAN & RENSHAW EQUITY RESEARCH 5

6. Amylin Pharmaceuticals Inc. May 21, 2012
Table 4. Total Prescriptions (TRx) for the GLP-1 Market by Week
GLP-1 Agonist - Total Rx (TRx)
Product 1/6/2012 1/13/2012 1/20/2012 1/27/2012 2/3/2012 2/10/2012 2/17/2012 2/24/2012 3/2/2012 3/9/2012 3/16/2012 3/23/2012 3/30/2012 4/6/2012 4/13/2012 4/20/2012 4/27/2012 5/4/2012 5/11/2012
Week 1 2 3 4 5 6 7 8 9 10 11 12 13
BYDUREON
TOTAL BYDUREON Rx 1 15 387 903 1,284 1,881 2,235 2,797 3,291 3,702 3,775 4,247 4,746 5,155 5,043
Sequential Growth 133.33% 42.19% 46.50% 18.82% 25.15% 17.66% 12.49% 1.97% 12.50% 11.75% 8.62% -2.17%
4-wk Moving Avg. Bydureon 134 327 647 1,114 1,576 2,049 2,551 3,006 3,391 3,754 4,118 4,481 4,798
BYETTA
10MCG/0.04 22,680 21,602 21,029 20,736 23,378 21,115 20,663 20,323 21,902 22,357 20,244 20,090 21,126 21,428 19,637 19,519 20,003 21,345 19,501
5MCG/0.02 7,145 6,893 6,911 6,718 7,446 6,982 6,729 6,539 7,107 7,222 6,629 6,666 6,864 6,887 6,119 6,330 6,376 6,969 6,389
TOTAL BYETTA Rx 29,825 28,495 27,940 27,454 30,824 28,097 27,392 26,862 29,009 29,579 26,873 26,756 27,990 28,315 25,756 25,849 26,379 28,314 25,890
Sequential Growth 10.27% -4.46% -1.95% -1.74% 12.28% -8.85% -2.51% -1.93% 7.99% 1.96% -9.15% -0.44% 4.61% 1.16% -9.04% 0.36% 2.05% 7.34% -8.56%
4-wk Moving Avg. 28,465 28,504 28,327 28,429 28,678 28,579 28,442 28,294 27,840 28,211 28,081 28,054 27,800 27,484 27,204 26,978 26,575 26,575 26,608
TOTAL EXENETIDE FRANCHISE 29,825 28,495 27,940 27,454 30,825 28,112 27,779 27,765 30,293 31,460 29,108 29,553 31,281 32,017 29,531 30,096 31,125 33,469 30,933
Sequential Growth 10.27% -4.46% -1.95% -1.74% 12.28% -8.80% -1.18% -0.05% 9.10% 3.85% -7.48% 1.53% 5.85% 2.35% -7.76% 1.91% 3.42% 7.53% -7.58%
4-wk Moving Avg. 28,465 28,504 28,327 28,429 28,679 28,583 28,543 28,620 28,487 29,324 29,657 30,104 30,351 30,490 30,596 30,731 30,692 31,055 31,406
VICTOZA
2-PACK 12,317 12,211 12,100 11,831 12,815 12,625 12,277 12,446 12,762 13,557 12,636 12,822 12,974 12,995 12,935 13,327 13,097 13,709 13,456
3-PACK 24,536 23,842 23,804 23,393 24,900 25,045 24,585 24,212 25,490 26,407 25,209 25,399 25,966 26,030 25,180 26,112 26,141 27,303 26,421
TOTAL VICTOZA Rx 36,853 36,053 35,904 35,224 37,715 37,670 36,862 36,658 38,252 39,964 37,845 38,221 38,940 39,025 38,115 39,439 39,238 41,012 39,877
Sequential Growth 11.49% -2.17% -0.41% -1.89% 7.07% -0.12% -2.14% -0.55% 4.35% 4.48% -5.30% 0.99% 1.88% 0.22% -2.33% 3.47% -0.51% 4.52% -2.77%
4-wk Moving Avg. 35,358 35,510 35,466 36,009 36,224 36,628 36,868 37,226 37,361 37,934 38,180 38,571 38,743 38,508 38,575 38,880 38,954 39,451 39,892
TOTAL GLP-1 Rx 66,678 64,548 63,844 62,678 68,540 65,782 64,641 64,423 68,545 71,424 66,953 67,774 70,221 71,042 67,646 69,535 70,363 74,481 70,810
Sequential Growth 10.94% -3.19% -1.09% -1.83% 9.35% -4.02% -1.73% -0.34% 6.40% 4.20% -6.26% 1.23% 3.61% 1.17% -4.78% 2.79% 1.19% 5.85% -4.93%
4-wk Moving Avg. 63,823 64,014 63,793 64,437 64,903 65,211 65,410 65,847 65,848 67,258 67,836 68,674 69,093 68,998 69,171 69,611 69,647 70,506 71,297
% of TRx by Product
Product 1/6/2012 1/13/2012 1/20/2012 1/27/2012 2/3/2012 2/10/2012 2/17/2012 2/24/2012 3/2/2012 3/9/2012 3/16/2012 3/23/2012 3/30/2012 4/6/2012 4/13/2012 4/20/2012 4/27/2012 5/4/2012 5/11/2012
Week 1 2 3 4 5 6 7 8 9 10 11 12 13
BYDUREON 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.60% 1.40% 1.87% 2.63% 3.34% 4.13% 4.69% 5.21% 5.58% 6.11% 6.75% 6.92% 7.12%
BYETTA 44.7% 44.1% 43.8% 43.8% 45.0% 42.7% 42.4% 41.7% 42.3% 41.4% 40.1% 39.5% 38.6% 39.9% 38.1% 37.2% 37.5% 38.0% 36.6%
Total Exenetide % 44.7% 44.1% 43.8% 43.8% 45.0% 42.7% 43.0% 43.1% 44.2% 44.0% 43.5% 43.6% 43.3% 45.1% 43.7% 43.3% 44.2% 44.9% 43.7%
VICTOZA 55.3% 55.9% 56.2% 56.2% 55.0% 57.3% 57.0% 56.9% 55.8% 56.0% 56.5% 56.4% 56.8% 54.9% 56.3% 56.7% 55.8% 55.1% 56.3%
RODMAN & RENSHAW EQUITY RESEARCH 6

7. Amylin Pharmaceuticals Inc. May 21, 2012
Table 5. Comparison of Bydureon and Victoza Launches by NRx
NRx by Week Since Launch
1 2 3 4 5 6 7 8 9 10 11 12 13
2/17/2012 2/24/2012 3/2/2012 3/9/2012 3/16/2012 3/23/2012 3/30/2012 4/6/2012 4/13/2012 4/20/2012 4/27/2012 5/4/2012 5/11/2012
Bydureon 386 894 1,275 1,845 2,073 2,467 2,719 2,940 2,801 2,963 3,224 3,332 3,161
% Sequential Growth 131.6% 42.6% 44.7% 12.4% 19.0% 10.2% 8.1% -4.7% 5.8% 8.8% 3.3% -5.1%
2/19/2010 2/26/2010 3/5/2010 3/12/2010 3/19/2010 3/26/2010 4/2/2010 4/9/2010 4/16/2010 4/23/2010 4/30/2010 4/30/2010 5/14/2010
Victoza 411 1,057 1,465 2,234 2,540 3,153 3,605 3,809 4,346 4,742 5,214 5,686 6,065
% Sequential Growth 157.2% 38.6% 52.5% 13.7% 24.1% 14.3% 5.7% 14.1% 9.1% 10.0% 9.1% 6.7%
Bydureon Performance Relative to Victoza -15.4% -13.0% -17.4% -18.4% -21.8% -24.6% -22.8% -35.5% -37.5% -38.2% -41.4% -47.9%
RODMAN & RENSHAW EQUITY RESEARCH 7

8. Amylin Pharmaceuticals Inc. May 21, 2012
RODMAN & RENSHAW RATING SYSTEM: Rodman & Renshaw employs a three tier rating system for evaluating both the potential
return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a
RELATIVE basis of other companies in the same sector, as defined by First Call. The price objective is calculated to estimate the potential
movement in price a given equity could achieve given certain targets are met over a defined time horizon. Price objectives are subject to
exogenous factors including industry events and market volatility. The risk assessment evaluates the company specific risk and accounts
for the following factors, maturity of market, maturity of technology, maturity of firm, cash utilization, and valuation considerations.
Potential factors contributing to risk: relatively undefined market, new technologies, immature firm, high cash burn rates, intrinsic value
weighted toward future earnings or events.
RETURN ASSESSMENT
q
Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the
common stock of companies within the same sector, as defined by First Call.
q
Market Perform (Hold): The common stock of the company is expected to mimic the performance of a passive index comprised
of all the common stock of companies within the same sector, as defined by First Call.
q
Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all
the common stock of companies within the same sector, as defined by First Call.
RISK ASSESSMENT
q
Speculative - The common stock risk level is significantly greater than market risk. The stock price of these equities is
exceptionally volatile.
q
Aggressive - The common stock risk level is materially higher than market level risk. The stock price is typically more volatile
than the general market.
q
Moderate - The common stock is moderately risky, or equivalent to stock market risk. The stock price volatility is typically in-line
with movements in the general market.
Rating and Price Target History for: Amylin Pharmaceuticals Inc. (AMLN) as of 05-18-2012
01/05/12 04/27/12
I:MU:$8 MU:$22
30
25
20
15
10
5
Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2
2010 2011 2012
Created by BlueMatrix
RATING SUMMARY
Distribution of Ratings Table
IB Serv./Past 12 Mos
Rating Count Percent Count Percent
Market Outperform(MO) 74 64.35% 10 13.51%
Market Perform(MP) 28 24.35% 3 10.71%
Market Underperform(MU) 6 5.22% 0 0.00%
Under Review(UR) 7 6.09% 2 28.57%
Total 115 100% 15 100%
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of
securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its
RODMAN & RENSHAW EQUITY RESEARCH 8

9. Amylin Pharmaceuticals Inc. May 21, 2012
affiliates or subsidiaries within the past 12 months.
ADDITIONAL DISCLOSURES
Rodman & Renshaw, LLC. (the "Firm") is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.
ANALYST CERTIFICATION
I, Michael G. King, Jr., hereby certify that the views expressed in this research report accurately reflect my personal views about the
subject company(ies) and its (their) securities.
None of the research analysts or the research analyst's household has a financial interest in the securities of Amylin Pharmaceuticals Inc.
(including, without limitation, any option, right, warrant, future, long or short position).
As of Apr 30 2012 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Amylin
Pharmaceuticals Inc..
Neither the research analyst nor the Firm has any material conflict of interest with Amylin Pharmaceuticals Inc., of which the research
analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific
investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a
substantial portion of which is derived from investment banking services.
The Firm or its affiliates did not receive compensation from Amylin Pharmaceuticals Inc. for any investment banking services within twelve
months before, but intends to seek compensation from the companies mentioned in this report for investment banking services within
three months, following publication of the research report.
Neither the research analyst nor any member of the research analyst's household nor the Firm serves as an officer, director or advisory
board member of Amylin Pharmaceuticals Inc..
The Firm does make a market in Amylin Pharmaceuticals Inc. securities as of the date of this research report.
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Reproduction without written permission is prohibited. The closing prices of securities mentioned in this report are as of May 21 2012.
Additional information is available to clients upon written request. For complete research report on Amylin Pharmaceuticals Inc., please
call (212) 356-0500.
Readers are advised that this analysis report is issued solely for informational purposes and is not to be construed as an offer to sell or
the solicitation of an offer to buy. The information contained herein is based on sources which we believe to be reliable but is not
guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance
is no guarantee of future results.
RODMAN & RENSHAW EQUITY RESEARCH 9